Thrombotic Thrombocytopenic Purpura (TTP)

Effects of Octaplas as primary treatment of acute TTP1

  • Single center, open label, non-randomized, case report study of 3 patients with acute TTP (one E coli-induced)
  • Patients were treated with Octaplas (3 L per day) plasma infusion or exchange until stable remission was achieved (normal platelet count and stable hemoglobin concentration) and resolution of neurological symptoms if present at diagnosis
STUDY OBJECTIVES: ASSESS EFFICACY, SAFETY, AND
TOLERABILITY OF OCTAPLAS IN PATIENTS WITH TTP
Patient Population
Age/Sex64 years/M36 years/M25 years/F
Platelet count (x109/L)188 19
Hemoglobin (g/dL)8.411.0 13.7
Octaplas
Dosage3 L daily3 L daily3 L daily
Normal platelet count (≥150×109/L)
Achieved on day73 10

Conclusions

  • All three patients attained platelet counts of > 50 x 109/L by day 10
  • All patients remained in remission for at least one post-treatment year
  • No patient experienced febrile or other adverse reactions to Octaplas
  • No viral transmission/infections
icon-freetrial Created with Sketch.

How to Order

Available in 200 mL bags in A, B, O and AB blood groups

Click here for ordering information
Reference:
  1. Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Haematol. 1999;21:119-123.